Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)(aEuro)

摘要

Patients with newly diagnosed, advanced non-small-cell lung cancer (NSCLC) were randomized to receive cisplatin or carboplatin with paclitaxel either at 200 mg/m(2) or pharmacokinetically (PK)-guided dosing. Study intervention resulted in a substantial decrease in neuropathy (grade a parts per thousand yen2 from 38% to 23%, P < 0.001), suggesting PK-guided dosing of paclitaxel to improve the benefit-risk profile in patients with advanced NSCLC.Variable chemotherapy exposure may cause toxicity or lack of efficacy. This study was initiated to validate pharmacokinetically (PK)-guided paclitaxel dosing in patients with advanced non-small-cell lung cancer (NSCLC) to avoid supra- or subtherapeutic exposure.